A New Weapon for Psoriasis Treatment | How Icotyrokinra Is Advancing Psoriasis Care into the Era of Precision Treatment

On August 27, 2026, a major milestone was reached in the field of psoriasis treatment in China. Johnson & Johnson officially announced that Icotrokinra (艾特雅®, ICOTYDE), also known as icotrokinra tablets hydrochloride and developed as JNJ-2113, had received approval from China’s National Medical Products Administration (NMPA).

As the world’s first and currently only approved oral IL-23 receptor-targeted therapy, Icotrokinra combines the targeted therapeutic potential traditionally associated with biologics with the convenience of oral administration. It has been described as a “biologic in a pill,” opening a new chapter for precision oral treatment of moderate-to-severe psoriasis.

🤔 The approval also raises an important question: how icotyrokinra is advancing psoriasis care into the era of precision treatment and what this new therapy could mean for patients and the psoriasis treatment landscape.

Icotrokinra: Key Product Profile and Basic Information

Icotrokinra (generic name: icotrokinra tablets hydrochloride; development code: JNJ-2113) is a first-in-class oral cyclic peptide therapy jointly developed by Johnson & Johnson and Protagonist Therapeutics.

The drug specifically targets the interleukin-23 receptor (IL-23R), an important component of the IL-23/Th17 inflammatory pathway involved in psoriasis. By selectively binding to IL-23R, icotrokinra is designed to inhibit inflammatory signaling associated with psoriasis and help reduce skin inflammation and psoriatic lesions.

👉 Unlike conventional oral immunosuppressive therapies, icotrokinra represents a different therapeutic approach, combining the convenience of an oral tablet with highly targeted biological activity.

Category	Details
Generic Name	Icotrokinra tablets hydrochloride
English Generic Name / Development Code	Icotrokinra (JNJ-2113)
Brand Name	ICOTYDE® (艾特雅®)
Drug Type	First-in-class oral IL-23 receptor antagonist / targeted peptide therapy
Primary Target	Interleukin-23 receptor (IL-23R)
Mechanism of Action	Selective inhibition of the IL-23/Th17 inflammatory pathway to help control inflammation and improve psoriatic lesions and related symptoms
China Approval Date	August 27, 2026
Approved Indication	Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; also approved for certain patients aged 12 years and older weighing ≥40 kg
Administration	Once-daily oral administration
Developed By	Johnson & Johnson and Protagonist Therapeutics

The Treatment Challenges in Psoriasis: A Long-Standing Clinical Gap

Psoriasis is a chronic, immune‑mediated systemic inflammatory skin disorder affecting a large patient population. The total number of patients exceeds several million, and approximately 25% of them suffer from moderate‑to‑severe plaque‑type psoriasis.

Characterized by frequent recurrence and severe pruritus, the disease severely impairs patients’ appearance and daily life. It also predisposes patients to multiple comorbidities including depression, anxiety, arthropathy and cardiovascular diseases, creating long‑term burdens on physical and mental well‑being.

For a long time, notable unmet medical needs have existed in the treatment of moderate‑to‑severe psoriasis.

• Topical agents only relieve superficial symptoms, with diminishing efficacy upon repeated use and failure to control underlying inflammation.
• Conventional oral immunosuppressants carry substantial side‑effects and lack target specificity, posing considerable risks for long‑term administration.
• IL‑23/IL‑17 biologics, which deliver optimal clinical outcomes, are all injectable formulations. Many patients experience injection phobia, inconvenience of repeated hospital visits, and poor adherence to home‑based injections.

👉 Consequently, a large number of patients remain in a therapeutic gap where topical treatments prove ineffective yet they are reluctant to initiate injectable biologic therapy, resulting in inadequate sustained disease management.

The launch of ICOTYDE® precisely fills the unmet gap for targeted oral therapy between topical medications and injectable biologics, offering patients a brand‑new systemic treatment option that combines high efficacy, favourable safety profile and convenient administration.

Strong Clinical Evidence: High Rates of Skin Clearance with an Oral Targeted Therapy

The Chinese approval of icotrokinra was supported by data from the global ICONIC Phase 3 clinical development program, which evaluated the therapy in adults and adolescents with moderate-to-severe plaque psoriasis. The program included placebo-controlled studies as well as a head-to-head comparison with deucravacitinib, providing evidence on both efficacy and safety.

1. Global Efficacy Data

• At Week 16, 64.7% of patients receiving icotrokinra achieved IGA 0/1, indicating clear or almost clear skin, while 49.6% achieved PASI 90, representing at least a 90% improvement in psoriasis severity.By comparison, the corresponding rates in the placebo group were 8.3% and 4.4%.
• At Week 24, the response continued to improve, with 74.1% of patients achieving IGA 0/1 and 64.9% achieving PASI 90.
• At Week 52, PASI 90 maintenance rates were reported to reach approximately 84% in adults and 86% in adolescents.

These findings suggest that the clinical benefits of icotrokinra can continue to increase over time rather than being limited to the early treatment period.

2. Data in Chinese Patients

Subgroup data from the ICONIC‑LEAD trial in local patients demonstrate that ICOTYDE® is highly well‑adapted for this patient population:

Significant improvement in skin lesions can be observed as early as Week 4, indicating rapid onset of action.

• At Week 16, 85.1% of Chinese patients achieved IGA 0/1, and 71.6% attained PASI 90. The rates of complete skin‑lesion clearance (IGA 0) and PASI 100 response reached 49.3 % and 38.8 %, respectively.
• For refractory scalp psoriasis, a highly prevalent condition locally, the scalp‑lesion clearance rate stood at 82.3 % at Week 16, precisely addressing this challenging clinical unmet need.
• Approximately 70% of Chinese patients achieved complete skin‑lesion clearance at Week 24, yielding clinical‑remission‑level therapeutic outcomes.

These results highlight the potential value of targeted oral therapy for patients with difficult-to-control psoriasis, although individual treatment responses may vary.

3. Head-to-Head Comparison with Deucravacitinib

In a head-to-head clinical study against deucravacitinib, icotrokinra demonstrated superior efficacy on key psoriasis endpoints.

At Week 16, the rates of IGA 0/1 and PASI 90 responses were higher with icotrokinra than with the comparator. This is particularly important because oral targeted therapies have historically faced a perception that their efficacy may not match that of injectable biologics. Icotrokinra may therefore represent an important step toward bringing biologic-like targeted efficacy into an oral treatment format.

4. Safety and Tolerability

Safety is another important consideration for any long-term psoriasis treatment.

In the clinical program, the overall safety profile of icotrokinra was reported to be favorable, with adverse-event rates at Week 16 broadly similar between the treatment and placebo groups. Reported adverse events included headache, nausea, cough, mild fungal infections, and fatigue.

As with any prescription medicine, however, treatment decisions should be based on the patient’s individual medical history, potential risks, and the assessment of a qualified healthcare professional.

Overall, the clinical evidence suggests that icotrokinra combines several potentially important characteristics: rapid improvement, high rates of skin clearance, sustained efficacy, oral administration and a targeted mechanism of action.

A New Option for Adolescents with Psoriasis

Adolescent psoriasis patients have unique physical and psychological developmental needs, exhibit stronger resistance to injectable therapies, and suffer greater mental‑health impacts from the disease. Clinically, there has long been a lack of safe and effective medications tailored for this population.

Icotrokinra is the first systemic anti‑psoriatic agent in the region to complete Phase III registration trials for both adults and adolescents simultaneously. It is approved for adolescents aged 12 years and older with a body weight of at least 40 kg, filling the gap for targeted therapeutic options in adolescent patients.

Impressive clinical outcomes have been observed in adolescent cohorts:

• 84.1% of adolescent patients achieved IGA 0/1, and 70.5% attained PASI 90 at Week 16.
• At Week 24, 75% reached complete skin‑lesion clearance (IGA 0), and 63.6% achieved 100% lesion clearance (PASI 100). It delivers robust efficacy with a safety profile consistent with that seen in adults, with no adolescent‑specific adverse events, making it a preferred oral treatment for moderate‑to‑severe psoriasis in adolescents.

These results indicate strong skin-clearance responses in adolescent patients, while continued safety monitoring remains important during long-term treatment.

Market Impact and Industry Outlook: Reshaping the Landscape of Precision Psoriasis Treatment

As the world’s first oral IL-23 receptor-targeted peptide therapy, the approval of Icotrokinra® in China represents more than an important milestone in Johnson & Johnson’s immunology pipeline. It also marks a significant development in the evolution of psoriasis treatment in China.

With its combination of oral convenience, strong skin-clearance efficacy, favorable safety profile and potential for long-term disease control, Icotrokinra addresses several limitations associated with conventional treatment approaches. It has the potential to create meaningful changes across clinical practice, patient experience and the broader psoriasis treatment landscape, while its ongoing clinical development may further expand its therapeutic applications.

Three Key Areas of Clinical and Industry Impact

• Lowering barriers to targeted therapy and improving patient adherence.
  • By eliminating the injection dependence associated with conventional biologics, it effectively addresses key pain points, including injection phobia, frequent hospital visits, and poor adherence to home‑based treatment. A large number of patients with moderate‑to‑severe psoriasis who have long stayed in the therapeutic gap can easily initiate standardized targeted systemic therapy, which helps prevent recurrent disease progression and worsening comorbidities.
• Breaking formulation‑efficacy barriers and raising the performance benchmark for oral therapies.
  • Overcoming the limitations of traditional oral agents such as modest efficacy, insufficient target selectivity and prominent adverse effects, it delivers biologic‑grade potency in an oral tablet. Its skin‑clearing efficacy is comparable to leading injectable targeted therapies, alongside a placebo‑comparable safety profile, making it well‑suited for long‑term disease maintenance in this chronic psoriasis condition.
• Optimizing the treatment pathway to enable full‑cycle targeted disease management.
  • Filling the therapeutic gap between topical preparations and injectable biologics, it forms effective complementarity with existing treatment modalities. It covers diverse patient groups, including adults, adolescents, cases with refractory lesions, and patients across mild‑to‑severe disease spectrums, establishing a stratified, targeted and long‑acting full‑cycle clinical management system for psoriasis.

In terms of long‑term growth potential, the clinical application landscape of Icotrokinra continues to expand. Its current core approved indication is moderate‑to‑severe plaque psoriasis. Leveraging the broad anti‑inflammatory properties of IL‑23 pathway inhibition, late‑stage clinical trials are underway for multiple IL‑23‑driven autoimmune conditions, including psoriatic arthritis, ulcerative colitis and Crohn’s disease, pointing to substantial potential for future indication expansions.

💰 Supported by compelling clinical data, industry projections estimate that the drug’s peak annual sales could exceed USD 5 billion, positioning it as a next‑generation flagship asset within Janssen’s autoimmune portfolio.

✨ Overall, the domestic launch of Icotrokinra (艾特雅®, ICOTYDE) delivers a true three‑dimensional upgrade for psoriasis treatment encompassing convenience, safety, and high efficacy. It advances local psoriasis care from conventional symptom‑oriented control toward a new era of targeted precision therapy and long‑term disease maintenance. It brings new therapeutic hope to millions of patients suffering from autoimmune disorders and injects fresh momentum into the development of targeted dermatological treatment.

Professional Pharmaceutical Supply and Procurement Support

Following its approval in China, demand for compliant, reliable, and stable access to innovative specialty medicines may continue to grow among qualified healthcare institutions, pharmaceutical distributors, and professional procurement organizations.

DengYue Pharmacy focuses on the pharmaceutical supply chain for innovative medicines, specialty drugs and targeted therapies. For qualified institutional and professional buyers, our services may include product availability inquiries, compliant procurement coordination, cross-border logistics support and professional after-sales assistance.

Our goal is to help qualified partners access innovative therapies through a professional and compliant pharmaceutical supply chain.

Contact

Conclusion

As the first and only oral IL-23 receptor-targeted peptide drug in the world, Icotrokinra® (Icotrokinra Tablets Hydrochloride) has reshaped the treatment landscape for moderate-to-severe plaque psoriasis in China through its differentiated product profile.

Compared with traditional topical medicines, conventional oral inhibitors and injectable biologics, Icotrokinra® effectively addresses the key limitations of previous treatments, including insufficient efficacy, significant side effects, inconvenient administration and poor treatment adherence. It combines five major advantages: the convenience of oral administration, biologic-level strong efficacy, placebo-level safety, both short- and long-term disease control, and suitability across a broad patient population.

✨ At the same time, the drug’s development across multiple indications also indicates its significant potential for expansion in the field of autoimmune diseases. The introduction of Icotrokinra® represents a major upgrade in psoriasis treatment, moving from traditional symptomatic control toward precision targeting, safe and long-lasting disease control, and comprehensive disease management throughout the treatment journey.

It provides patients with psoriasis with a higher-quality and more patient-friendly new treatment option, while also providing new support for the innovative development of precision diagnosis and treatment in dermatology in China.

FAQ About How Icotyrokinra Is Advancing Psoriasis Care into the Era of Precision Treatment